One approach to improving the outcome of allogeneic hematopoietic stem-cell transplantation for acute lymphoblastic leukemia (ALL) is to intensify the pretransplant conditioning regimen without increasing toxicity. We used an intensified conditioning regimen consisting of high-dose cytosine arabinoside (3 g/m 2 twice daily i.v. for 3 consecutive days, total six doses), high-dose etoposide (1 g/m 2 once daily i.v. during the first 2 days) and total body irradiation (TBI) (HDACE-TBI) in ALL patients. We retrospectively analyzed 21 patients treated with HDACE-TBI, of whom 18 were in complete remission (CR) and three were in non-CR at transplantation. Although gastrointestinal toxicities were common, critical regimen-related toxicities were not seen in any patients. One patient demonstrated veno-occlusive disease, which could be controlled conservatively. The disease-free survival rate of 18 patients in CR at transplantation was 61%. These results demonstrate that the HDACE-TBI combination regimen is a feasible alternative to other preparatory regimens and does not increase the regimenrelated toxicity.
etoposide; hematopoietic stem-cell transplantation; acute lymphoblastic leukemia Marrow ablative therapy followed by allogeneic hematopoietic stem-cell transplantation (allo-HSCT) is one modality for treating patients with acute lymphoblastic leukemia (ALL) and is the most effective way of eliminating leukemia in the majority of patients. The effectiveness of allogeneic transplantation is, however, offset by the substantial early mortality caused by regimen-related toxicity and graft-versus-host disease (GVHD). Therefore, transplantation during first remission of ALL remains controversial. [1] [2] [3] The curative effect of allo-HSCT is derived partly from the antileukemic effect of myeloablative therapy and partly from a graft-versus-leukemia (GVL) effect; namely, an alloimmune response of donor immune cells to the residual leukemia. However, the GVL effect in ALL may be less powerful than that in other hematological malignancies and has only been demonstrated in conjunction with GVHD. Therefore, a preparative regimen that is sufficiently intensive to eradicate the leukemia cell burden entirely would be preferable for patients with ALL, particularly those at high risk. Here, we report a retrospective evaluation of the feasibility and toxicity of a new intensified combination regimen containing high-dose cytosine arabinoside (Ara-C), high-dose etoposide and total body irradiation (TBI) (HDACE-TBI) by analyzing the outcome of 21 patients with ALL.
Patients and methods

Patients
Between February 1992 and April 2000, 21 ALL patients were treated with allogeneic BMT or peripheral blood stem-cell transplantation (PBSCT) using the HDACE-TBI conditioning regimen.
In all, 13 patients were male and eight were female. The median age was 23 years (range 10-46 years), with 11 patients aged 10-20 years, eight aged 21-40 years and two patients older than 40 years. Nine patients were in first complete remission (CR), nine in second CR, two in third relapse and one had failed to ever attain CR with chemotherapy, including seven patients with Philadelphia (Ph) chromosome-positive ALL (Table 1 ). There were 17 related donors, while four patients received transplants using bone marrow from unrelated donors (URBMT). All patients received HLA-matched grafts (either related or unrelated). In total, 19 patients were treated with allo-BMT and two patients (UPN143 and 152) with allo-PBSCT.
Preparatory regimen
The HDACE-TBI regimen consisted of TBI, Ara-C and etoposide (VP-16) at high doses. TBI was administered in six fractions of 200 cGy (eight cases) or 220 cGy (13 cases) to a total dose of 12 or 13.2 Gy, respectively. The radiation dose was reduced to 12 Gy in eight cases because of age (older than 40 years, UPN 119 and 131), prior central nervous system (CNS) prophylaxis with cranial irradiation (UPN109), poor performance status at transplantation (UPN 143) ). Corticosteroid eye drops were used to reduce conjunctivitis. The combination chemotherapy was administered either before (15 cases) or after (six cases) TBI.
Transplantation
A total of 15 patients received bone marrow grafts from their respective histocompatible siblings, one (UPN152) from his histocompatible father and one (UPN143) from his sibling as a PBSC donor. Four patients received bone marrow from unrelated histocompatible donors. In the cases with a major blood group mismatch with the donor, the red cells were removed from the harvested marrow by centrifugation in a cell separator.
Supportive therapy
Post transplant immunosuppression to prevent GVHD consisted of cyclosporin A (CsA) (1.5 mg/kg i.v. every 12 h from day À1) alone in seven patients and as a combination of CsA and methotrexate (MTX) (15 mg/m 2 i.v. on day þ 1, 10 mg/m 2 i.v. on day þ 3, þ 6 and þ 11) in 14 patients. In total, 19 patients received granulocyte colonystimulating factor (G-CSF). All patients were treated with heparin prophylaxis for veno-occlusive disease (VOD) by continuous infusion of 100 U/kg/24 h from day À7 to þ 30.
Evaluation of engraftment
Engraftment was evaluated by daily blood counts. The recovery day was the day when the neutrophil count became greater than 0.5 Â 10 9 /l, the platelet count was greater than 50 Â 10 9 /l without transfusions and the reticulocyte count was 2%. A bone marrow aspirate and confirmatory cytogenetic studies were performed to assess engraftment. Further bone marrow evaluations were carried out if clinically indicated.
Analysis
Regimen-related toxicities other than stomatitis, nausea and vomiting were analyzed using Bearman's criteria. 4 Nausea, vomiting and stomatitis were graded using the National Cancer Institute Common Toxicity Criteria (NCI-CTC) Version 2.0.
5 Survival curves were drawn using the Kaplan-Meier method and P-values of survival curves were obtained using log-rank test. GVHD prophylaxis and acute GVHD were analyzed using the Mann-Whitney test. In all the analyses, a P-value of o0.05 was considered significant. All patients have been followed up for a minimum of 24 months since transplantation. /l without transfusion; Ret ¼ reticulocyte; the day when the reticulocyte count was more than 2%.
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Results
Engraftment
The range for white blood cell (WBC) engraftment was 10-27 days (median 17 days), platelets 19-197 days (median 35 days) and reticulocytes 17-67 days (median 30 days) ( Table 1 ). The donor graft was rejected in one URBMT patient (UPN109) who then achieved blood cell recovery (WBC, day 27; platelets, day 33; reticulocytes, day 33) and has been well without leukemic relapse for 6.5 years.
Early toxicity
Early toxicity (À7 up to 30 days post transplant), other than stomatitis that was related to the conditioning regimen was graded based on the regimen-related toxicity grading system 4 ( Table 2 ). Stomatitis, nausea and vomiting were graded using the criteria for BMT studies in NCI-CTC version 2.0 (Table 3) . Gastrointestinal (GI) toxicity as a result of the conditioning regimen was common. Grade I diarrhea was seen in all patients. A total of 18 patients (85%) experienced difficulties in swallowing or lost the ability to swallow due to severe stomatitis and required parenteral nutrition (Table 3) . Grade I nausea was seen in 24% of patients, grade II in 67% and grade III in 10%. Grade I vomiting was seen in 5% of patients, grade II in 71% and grade III in 24%, and all patients were treated with standard antiemetics. Grade I hepatic toxicity was seen in five patients (24%) and grade II in four patients (19%). Grade I cardiac toxicity was seen in nine patients (43%) and grade II and grade III were not observed. Grade I pulmonary toxicity was seen in four patients (19%). Although two patients developed high fever due to allergy to VP-16, corticosteroid treatment was effective. Bladder, renal and CNS toxicities were not observed. Critical toxicities, namely, grade III Bearman's toxicity and grade IV NCI-CTC criteria, were not seen. Only one patient had VOD, which was severe with a peak bilirubin of greater than 10 mg/dl, with hepatomegaly and body weight gain. She was treated conservatively with corticosteroids and improved.
GVHD
In total, 11 patients developed acute GVHD; four (19%) had grade I, five (24%) had grade II, one (5%) had grade III and one (5%) had grade IV. Severe acute GVHD, over grade III, occurred in two (9.5%) patients with this regimen (Table 4) . Acute GVHD was significantly more severe in the patients who received CsA alone rather than those using CsA and MTX (P ¼ 0.0055). One patient (UPN 101) died from grade IV acute GVHD. Therefore, we used CsA and MTX for the prophylaxis of acute GVHD after this patient (except for one patient without CR (UPN 134)). Six out of 21 patients (28.6%) developed chronic GVHD; three had limited type and three had extensive type. One patient (UPN97) with chronic GVHD who developed bronchiolitis obliterans improved after treatment with corticosteroids. Idiopathic pneumonia syndrome developed 2 years after URBMT in another chronic GVHD patient (UPN159), who has so far responded well to outpatient treatment with small doses of corticosteroids.
Relapse
Overall, nine of the 21 patients relapsed. Six out of 18 patients in CR and all three patients not in CR at transplantation relapsed (Table 4) . Seven of the nine relapses occurred within the first year after transplantation. Extramedullary relapse occurred in two patients (UPN129 and 167, pleural effusion and CNS, respectively) on days +572 and þ 529, respectively. The latter patient was treated with intrathecal chemotherapy and radiation, and has been alive in CR.
Survival
In all, 12 patients (57%) are alive and nine (43%) died, with a mean follow-up of 71.2 months (range 24-117.5 months) among the patients. DFS of the 18 patients in CR at transplantation was 61% (Figure 1 ). However, all three patients not in CR at transplantation died from relapse. Radiation doses between 12 and 13.2 Gy did not affect DFS significantly (P ¼ 0.91) (data not shown).
Discussion
The primary purpose of this study was to determine the tolerability and toxicity of high-dose Ara-C, high-dose VP-16 and TBI as a myeloablative regimen. GI toxicity as a result of this conditioning regimen was common. As a morphine drip was not used in our institute until 1996, we could not evaluate the toxicity of stomatitis using Bearman's criteria. Therefore, we analyzed it using the NCI-CTC criteria for BMT studies. Grade II and III nausea and vomiting were seen in most of our patients and grade III Table 2 Nonhematologic toxicity (n ¼ 21)
Organ system Total (%) Grade I (%) Grade II (%) Grade III (%) All toxicities were graded using Bearman's criteria. GI ¼ gastrointestinal; CNS ¼ central nervous system.
Table 3
Nausea/vomiting/stomatitis Nausea  0  0  5  24  14  67  2  10  0  0  Vomiting  0  0  1  5  15  71  5  24  0  0  Stomatitis  0  0  0  0  3  15  18  85  0  0 Nausea, vomiting and stomatitis are graded using the National Cancer Institute Common Toxicity Criteria (NCI-CTC Version 2.0).
Grade (%) 0 (%) I (%) II (%) III (%) IV (%)
High-dose Ara-C and etoposide with TBI regimen for ALL N Sato et al stomatitis was observed in 85% of patients. No one, however, required preventive intubation or was documented as having aspiration pneumonia. Critical toxicities were not seen in any patients. Furthermore, no additional toxic effects were observed in patients treated with 13.2 Gy irradiation. These results indicate that this regimen is sufficiently feasible to compare with other preparative regimens.
We intensified the conditioning regimen by adding highdose Ara-C to the regimen containing TBI and high-dose VP-16. The combination of TBI and high-dose VP-16 seemed to be effective for advanced stages of ALL, and a number of reports have confirmed the low relapse rate in patients with high-risk ALL. [6] [7] [8] High-dose Ara-C is an effective induction therapy as well as consolidation therapy for ALL patients with poor risk prognostic factors. 9, 10 Furthermore, the conditioning regimen using TBI and high cumulative doses of Ara-C of 24 or 36 g/m 2 resulted in a lower relapse rate, especially in young adults. 11, 12 Therefore, the combination of TBI, high-dose VP-16 and highdose Ara-C could be expected to reduce the relapse rate. However, fatal pulmonary failure was observed in patients receiving high-dose Ara-C for acute leukemia. 13 In addition, a significant proportion of allogeneic or autologous BMT patients whose conditioning regimen contained high cumulative doses of Ara-C of 36 g/m 2 died early as a result of toxicity. Pulmonary complications including interstitial pneumonia and obvious infections and the risk of pulmonary toxicity increased with age. [14] [15] [16] [17] We therefore reduced the total dose of Ara-C to 18 g/m 2 in this study. In our study, although the early grade I pulmonary toxicities seen in four patients were not critical, two other patients suffered from late pulmonary complications and needed corticosteroid therapy to control their symptoms. Since only two patients were older than 40 years, the toxicity of this combination regimen in older patients remains to be evaluated.
A GVL effect in preventing relapse in patients with ALL was first suspected by the observations of a higher relapse rate after autologous or syngeneic HCT compared to allogeneic HCT, and an increased relapse rate in recipients of T-cell-depleted marrow grafts. The most compelling argument for a strong GVL effect in ALL comes from data showing a lower relapse rate in patients who have had GVHD. [18] [19] [20] [21] However, unlike the situation in chronic myelogenous leukemia and acute myelogenous leukemia, where complete responses are often seen, donor lymphocyte infusion for relapsed ALL rarely, if ever, leads to CR. 22, 23 These observations suggest that the GVL effect in ALL may be less powerful than in other hematological malignancies. Therefore, a preparative regimen should be sufficiently intensive to provide enough leukemia cell reduction to allow the patients an interval for reconstitution of immunological function to prevent relapse. Indeed in our patients, the relapse rate in the patients with chronic GVHD (cGVHD) (one out of six patients) was less than that in the patients without cGVHD (four out of 10), which, although numbers were small, suggested that cGVHD had been beneficial in preventing relapse. The high-dose Ara-C, high-dose VP-16 and TBI regimen was well tolerated and not associated with specific acute or long-term regimen-related toxicities. Although the population analyzed was heterogeneous and recruited over a long period of time in one institute, our data suggest that this combination regimen represents a viable alternative to other conditioning regimens containing CY and TBI. This intensified combination regimen warrants further prospective study to determine the antileukemic effect in patients with ALL.
